Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Tablets have always been the poor relation in weight loss medicine. Injections produced the big numbers while pills delivered modest results with awkward side effects.
That changed in April 2026, when the first oral GLP-1 for weight management was approved. The tablet category is now worth taking seriously, and this guide compares every option honestly.
The comparison at a glance
| Pill | Mechanism | Weight loss | Trial |
|---|---|---|---|
| Orforglipron | GLP-1 receptor | up to 12.4 percent | ATTAIN-1, 72 wk |
| Qsymia | Appetite + food reward | 10.5 percent | SEQUEL, 108 wk |
| Contrave | Craving and reward | 6.1 percent | COR-I, 56 wk |
| Orlistat | Blocks fat absorption | 5.8 kg | XENDOS, 4 yr |
| Rybelsus | GLP-1 receptor | Modest, diabetes dose | Approved for diabetes |
These figures come from separate trials with different populations and durations, so read the ordering as approximate rather than exact.
Orforglipron
Approved by the FDA on 1 April 2026 for weight management, this is the significant new entry.
It is a small-molecule GLP-1 receptor agonist rather than a peptide, which is why it survives digestion and works as a tablet. In ATTAIN-1, the highest dose produced up to 12.4 percent average weight loss over 72 weeks.
Its practical advantage over Rybelsus is substantial. No food restrictions, no water limit, no waiting period. Rybelsus requires an empty stomach, a maximum of 120 ml of water, and nothing else for 30 minutes.
Side effects are the familiar GLP-1 pattern of nausea, diarrhoea, vomiting and constipation. It carries the class boxed warning about thyroid C-cell tumours.
It is not registered in Pakistan.
Qsymia
The strongest of the older tablets. It combines phentermine, a stimulant appetite suppressant, with topiramate, an anti-seizure drug that reduces food reward and alters taste.
In the SEQUEL trial, the 15/92 mg dose produced 10.5 percent average weight loss at 108 weeks against 1.8 percent on placebo. Two years of sustained loss is unusually good durability evidence.
Its restrictions are serious. Topiramate causes birth defects, so a negative pregnancy test before starting, monthly testing during treatment, and effective contraception throughout are mandatory. Cognitive side effects including word-finding difficulty are common, as are tingling in the hands and feet and altered taste, particularly of carbonated drinks.
Contrave
Combines naltrexone, an opioid receptor blocker, with bupropion, an antidepressant. It targets the brain's reward pathway rather than physical fullness.
In COR-I, it produced 6.1 percent at 56 weeks against 1.3 percent on placebo.
Its distinctive value is what it treats. For someone whose problem is craving, emotional eating or constant food thoughts rather than large portions, Contrave addresses the actual mechanism.
Its restrictions are also significant. Not used with a seizure history, an eating disorder, uncontrolled hypertension, opioid painkillers or MAOI antidepressants. It carries the antidepressant class warning about suicidal thoughts.
Orlistat
The oldest option, sold as Xenical at 120 mg on prescription and Alli at 60 mg over the counter.
It blocks lipase, the enzyme that breaks dietary fat into absorbable pieces, preventing roughly 30 percent of dietary fat from being absorbed. It is not absorbed into your bloodstream and has no effect on your brain or hormones.
The four-year XENDOS trial recorded 5.8 kg average loss against 3.0 kg on placebo, plus a 37.3 percent relative reduction in progression to type 2 diabetes.
Its side effects are entirely digestive and scale directly with fat intake: oily stools, urgency and wind. It blocks fat-soluble vitamins A, D, E and K, so a multivitamin taken hours apart is required.
Critically, it does nothing about carbohydrates, sugar or portion size.
Rybelsus
Oral semaglutide, approved for type 2 diabetes rather than weight management. Weight loss occurs but at diabetes doses rather than weight-management doses.
Its dosing protocol is genuinely disruptive: empty stomach, maximum 120 ml of water, nothing else for 30 minutes. Absorption is poor and easily disrupted. Orforglipron exists partly to solve this problem.
How to think about choosing
The mechanisms differ enough that the question is not which is strongest, but which matches why you overeat.
Large portions and genuine hunger point toward a GLP-1 mechanism. Orforglipron is the tablet option.
Craving, emotional eating, constant food thoughts point toward Contrave, which targets reward rather than fullness.
High fried and fatty food intake is what orlistat acts on directly.
Appetite plus difficulty with food reward is Qsymia's combined target, though its pregnancy restrictions rule it out for many.
Before considering any of these, confirm your starting BMI. Eligibility for every prescription option in this category is anchored to it, generally requiring 30 or above, or 27 and above with a weight-related condition.
What is available in Pakistan
This is where the comparison meets reality.
Orlistat is the most accessible. It needs no refrigeration, is not import-dependent, and generic versions are widely available. Its limitation is that it only addresses fat, and typical Pakistani eating patterns are frequently driven by refined carbohydrates, roti, rice and sugar as much as by fat.
Qsymia and Contrave have limited registered availability. Combining their component drugs independently is not a substitute for the fixed-dose controlled-release formulations and should not be attempted, because the release design is central to both effectiveness and safety.
Orforglipron and Rybelsus are not registered here.
That leaves a gap between what exists in the world and what you can obtain. METASLIM™ appetite support drops work on the GLP-1 pathway through sublingual absorption, with a physician reviewing every order before dispatch. It is a physician-reviewed supplement rather than a pharmaceutical tablet, so the trial figures in this article do not apply to it and should not be compared directly. Its relevance is that it addresses appetite, which orlistat does not, and it is actually obtainable here, which orforglipron is not.
Our detailed guides cover orlistat, Qsymia and Contrave individually.
The summary
Orforglipron is the strongest prescription tablet at up to 12.4 percent, and the first oral GLP-1 without dosing restrictions.
Qsymia leads the older tablets at 10.5 percent with two-year durability, at the cost of mandatory pregnancy precautions and cognitive side effects.
Contrave produces 6.1 percent and is the logical choice for craving-driven eating specifically.
Orlistat produces the least but is the most accessible, and does nothing for carbohydrate intake.
In Pakistan, accessibility rather than efficacy decides most of this.
Check the current price and what's included for a locally available comparison.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.